Results 131 to 140 of about 11,211 (144)

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

Journal of Clinical Pharmacology, 2015
Julie Borland, Stephen C Piscitelli, Ivy Song   +2 more
exaly  

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.

Clinical Infectious Diseases, 2014
Scott Letendre, K T Tashima, Ivy H Song
exaly  

Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients

HIV Clinical Trials, 2014
B Wynne
exaly  

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Open Forum Infectious Diseases, 2018
Tahaniyat Lalani, Jomy M George, Zehava Grossman   +2 more
exaly  

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

Journal of Antimicrobial Chemotherapy, 2019
Francesca Lombardi, Antonio D'Avolio, Stefano Bonora   +2 more
exaly  

Dolutegravir

Reactions Weekly
openaire   +2 more sources

Synthesis and Characterization of Potential Impurities of Dolutegravir: A HIV Drug

ChemistrySelect, 2018
Naveen Mulakayala
exaly  

Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection

Annals of Pharmacotherapy, 2014
Misty M Miller, Michelle D Liedtke
exaly  

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

HIV Medicine, 2017
exaly  

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

British Journal of Clinical Pharmacology, 2015
Brian Sadler, Sherene Min, Ivy H Song
exaly